Recce Pharmaceuticals Ltd. · ASX:RCE

Recce Pharmaceuticals — Investor Presentation (2016)

25 slides from Recce Pharmaceuticals's investor presentation, 2016

  1. Slide 1: Our Mission: To target the global health problem of superbugs

    Slide 1: Our Mission: To target the global health problem of superbugs

    Our Mission: “To target the global health problem of superbugs” “One of the greatest threats of human health today” World Health Organisation ASX: RCE 1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer ALL CURRENCY AMOUNTS ARE IN AUD UNLESS STATED OTHERWISE. DISCLAIMER This presentation has been prepared by Recce Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You

  3. Slide 3: Business Overview

    Slide 3: Business Overview

    Business Overview Why is RECCE® 327 important? • Continued use of commercial antibiotics has led to antibiotic-resistant bacteria – superbugs, a major world health issue • RECCE® 327 kills superbugs (G+ & G- bacteria) – and keeps-on killing them • RECCE® 327 is wholly synthetic • RECCE® 327 has show

  4. Slide 4: Corporate Overview

    Slide 4: Corporate Overview

    Corporate Overview Shares Market Capitalisation Cash & Deposits Enterprise Value (ASX: RCE) (@$0.27/share) (30 June 2016) 72.64M $19.61M $3.59M $16.02M 4

  5. Slide 5: Corporate Overview

    Slide 5: Corporate Overview

    Corporate Overview Validated patents in UK, Germany, France, Italy, Safety test shows no Spain, Sweden signs of toxicity 15/01/16 25/05/16 * r Rapid scale-up of RECCE® 327 manufacture achieved Recce Antibiotics kills, Top IPO Listing Pharma execiitive tb and gonorrhoea for 2016 Bemadette Murdoch 27/

  6. Slide 6: Technology: Very resistant – P. aeruginosa (Gr-ve superbug)

    Slide 6: Technology: Very resistant – P. aeruginosa (Gr-ve superbug)

    Technology: Very resistant – P. aeruginosa (Gr-ve superbug) Pre-infection Full infection After 1 hour treatment with RECCE® synthetic antibiotic Complete kill 6

  7. Slide 7: RECCE 327 kills at practical speeds

    Slide 7: RECCE 327 kills at practical speeds

    RECCE® 327 kills at practical speeds* Rates of kill of standard bacteria S. aureus E. coli P. aeruginosa S. pyogenes C. difficile 20 – 60 20 – 60 1 – 24 20 – 60 20 – 60 minutes minutes hours minutes minutes Rates of kill of Superbugs S. aureus E. coli P. aeruginosa The same kill-rates for standard b

  8. Slide 8: RECCE 327 does not Fail

    Slide 8: RECCE 327 does not Fail

    RECCE® 327 does not Fail Number of repetitive uses before displaying loss of antibiotic activity S. aureus E. coli P. aeruginosa Commercial Commercial Commercial antibiotic antibiotic antibiotic 8 4 10 RECCE® Antibiotic >25 After repetitive use, the commercial antibiotic loses activity; RECCE® 327 D

  9. Slide 9: Technology – How it works

    Slide 9: Technology – How it works

    Technology – How it works RECCE® antibiotics attack protein in the cell wall of bacteria – outward pressure in the bacteria, causes only them to rupture. 9

  10. Slide 10: Natural vs Synthetic

    Slide 10: Natural vs Synthetic

    Natural vs Synthetic • Commercial antibiotics are naturally derived – superbugs to them have been forming for millenniums – and will continue to do so • RECCE® 327 is wholly synthetic – superbugs never formed in nature – designed for a purpose! 10

  11. Slide 11: Manufacture

    Slide 11: Manufacture

    Manufacture 11

  12. Slide 12: Manufacture

    Slide 12: Manufacture

    Manufacture Highly economical patent-protected process, with key advantages: 1. ‘1 step’ process - Product produced in 1 hour only 2. 100% yield - No raw material losses - No purification steps - No waste disposal 3. Raw material in-expensive & plentiful 4. RECCE® Trademark registered - in global ma

  13. Slide 13: The Board

    Slide 13: The Board

    ece The Board eve 8

  14. Slide 14: Board of Directors

    Slide 14: Board of Directors

    Board of Directors Dr Graham Melrose, BSc(Hons), PhD, MBA, FRACI, CChem, FAICD Executive Chairman • Founder of Recce and inventor of RECCE® antibiotics • Executive Director and Chief Research Executive of Johnson & Johnson (Aust) Pty Ltd in Sydney, with global responsibilities, particularly in Asia-

  15. Slide 15: Board of Directors

    Slide 15: Board of Directors

    Board of Directors James Graham B.Com.(Entrepreneurship), GAICD Executive Director – Responsible for Marketing and Business Development • Founder in the early funding, growth and direction of Recce • Committee-member of W.A. Angel Investors, backers of Australian entrepreneurial companies • Formerly

  16. Slide 16: Board of Directors

    Slide 16: Board of Directors

    Board of Directors Dr Dominic Barnes MBBS, MMedSc, MBA, FAICD Independent Non-Executive Director • Practicing medical doctor and supervisor of over 20 human pharmaceutical trial programs • Directorships and senior regulatory appointments with leading pharmaceutical companies: Shire, AstraZeneca and

  17. Slide 17: Development

    Slide 17: Development

    Development 17

  18. Slide 18: Intellectual Property

    Slide 18: Intellectual Property

    Intellectual Property* Patent Attorneys: Phillips Ormonde Fitzpatrick - Melbourne Patent Family 1 Filed Status Expiry Australia Granted 2028 USA Granted 2029 Europe Granted 2028 Japan Granted 2028 China Granted 2028 Patent Family 2 All PCT Countries Pending 2034 Patent Family 3 Provisional *Manufact

  19. Slide 19: Human Markets ($170B)

    Slide 19: Human Markets ($170B)

    Human Markets ($170B) Enormous and Growing Market Potential 1. Antibiotics - around US$40b, estimated to climb 12.5% to US$45b by 2019 1 2. Anti-cancer - around US$100b, estimated to climb 50% to US$150b by 2018 2 3. Anti-viral - around US$30b, estimated to climb 333% to US$100b by 2025 3 1 BCC Rese

  20. Slide 20: RECCE antibiotics: Sepsis

    Slide 20: RECCE antibiotics: Sepsis

    RECCE® antibiotics Sepsis • “Sepsis affects over 26 million people worldwide each year - one third die”* • “It is the largest killer of children and new-born infants in the world” • “Sepsis is increasing at an annual rate of 8-13%” • “In the United States, sepsis kills more people than colon cancer,

  21. Slide 21: RECCE antibiotics

    Slide 21: RECCE antibiotics

    RECCE® antibiotics Three groups of 10 mice were each infected with S.aureus (superbug) • All ten mice treated with RECCE® antibiotic were saved • Nine mice treated with current antibiotic (Oxacillin) survived • Four mice that had no treatment at all, survived. In mice, Efficacy/Safety was achieved i

  22. Slide 22: RECCE anti-virus

    Slide 22: RECCE anti-virus

    RECCE® anti-virus RECCE® 327 vs Influenza, outside of VERO (Monkey) cells Conclusions from Industry standard Plaque- Reduction Neutralization Test Assay (PRNT) using Monkey cells: • RECCE® 327 may be used to target viruses located external to cells - common when the invading virus is located between

  23. Slide 23: RECCE anti-cancer

    Slide 23: RECCE anti-cancer

    RECCE® anti-cancer • Equal or better results than Tamoxifen Citrate, commercial antibiotic • RECCE® 327 did not cause toxicity in normal human epithelial cells or Vero (monkey) cells Results from an independent laboratory in USA 23

  24. Slide 24: RECCE – a Technology

    Slide 24: RECCE – a Technology

    RECCE® 327 – a Technology Compared to the risk of a single opportunity from a one-use product - Recce’s technology enjoys the added security of multiple product opportunities. 24

  25. Slide 25: Contact Details

    Slide 25: Contact Details

    Contact Details Head Office – Sydney Perth Office & Lab Washington Office Level 34, 50 Bridge Street Suite 10, 3 Brodie Hall Drive 1717 Pennsylvania Avenue AMP Centre Technology Park NW SYDNEY NSW 2000 BENTLEY WA 6102 Suite 1025 AUSTRALIA AUSTRALIA WASHINGTON DC 20006 USA Telephone: +61 (2) 8261 076

Source: Internet Archive copy of recce.com.au

More decks from Recce Pharmaceuticals Ltd.

All 45 Recce Pharmaceuticals decks